Cargando…
Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the dia...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630545/ https://www.ncbi.nlm.nih.gov/pubmed/28721687 http://dx.doi.org/10.1007/s13300-017-0277-0 |
_version_ | 1783269237714845696 |
---|---|
author | Gomez-Peralta, Fernando Abreu, Cristina Lecube, Albert Bellido, Diego Soto, Alfonso Morales, Cristóbal Brito-Sanfiel, Miguel Umpierrez, Guillermo |
author_facet | Gomez-Peralta, Fernando Abreu, Cristina Lecube, Albert Bellido, Diego Soto, Alfonso Morales, Cristóbal Brito-Sanfiel, Miguel Umpierrez, Guillermo |
author_sort | Gomez-Peralta, Fernando |
collection | PubMed |
description | Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed. |
format | Online Article Text |
id | pubmed-5630545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-56305452017-10-23 Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes Gomez-Peralta, Fernando Abreu, Cristina Lecube, Albert Bellido, Diego Soto, Alfonso Morales, Cristóbal Brito-Sanfiel, Miguel Umpierrez, Guillermo Diabetes Ther Practical Approach/CME Article Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed. Springer Healthcare 2017-07-18 2017-10 /pmc/articles/PMC5630545/ /pubmed/28721687 http://dx.doi.org/10.1007/s13300-017-0277-0 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Practical Approach/CME Article Gomez-Peralta, Fernando Abreu, Cristina Lecube, Albert Bellido, Diego Soto, Alfonso Morales, Cristóbal Brito-Sanfiel, Miguel Umpierrez, Guillermo Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title_full | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title_fullStr | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title_full_unstemmed | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title_short | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
title_sort | practical approach to initiating sglt2 inhibitors in type 2 diabetes |
topic | Practical Approach/CME Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630545/ https://www.ncbi.nlm.nih.gov/pubmed/28721687 http://dx.doi.org/10.1007/s13300-017-0277-0 |
work_keys_str_mv | AT gomezperaltafernando practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT abreucristina practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT lecubealbert practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT bellidodiego practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT sotoalfonso practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT moralescristobal practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT britosanfielmiguel practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes AT umpierrezguillermo practicalapproachtoinitiatingsglt2inhibitorsintype2diabetes |